Cancer Hospital In India

BIACH&RI firmly believes that Medical Education & research as well as high quality clinical services are the necessary components of a reputed Medical Institution. The doctors, Nurses and paramedical staff during their training in various authorized courses available in academic units of the Institute support clinical services during their training and help to meet the requirements of the Institute after completion of their training and degree/diploma. With this in view, BIACH&RI has obtained necessary authorization/accreditation for post graduate diploma super-speciality/general specialty courses for post graduate/graduate doctors, nurses and paramedical staff.

A well equipped in-house research lab working in tandem with clinicians has added advantage of ready availability of research medium in the form of tissue and other human samples as also the observations, insight and knowledge of clinicians obtained during their day to day medical work. It can help in giving leads to new research projects towards discoveries of new drugs or/and diagnostic and treatment modalities.


Research & Development

Vision:

To be an Effective World Class clinical and Translational Cancer Research center to Further the Drive Against Cancer

Mission:

• To make effective and significant contributions towards fight against cancer

• Develop newer and better strategies to identify cancer susceptible population to intervene and treat cancer patients so as to alleviate their pain and suffering.

• Develop and innovate cancer preventative strategies

• Uncovering anti-cancer properties of bioactive compounds and discover novel, effective anti-cancer drugs (with no/less side effects) using RNAi/ miRNA based approaches and adapting stem cell based adjuvant therapies.

• Developing/ adopting emerging molecular and biochemical diagnostic, prognostic, drug efficacy and drug toxicity tests based on pharmcogenetics/pharmacogenomics/proteomic approaches.

• Identifying extrinsic/ lifestyle factors that contribute to carcinogenesis, to develop cancer prevention strategies.

• Actively participating in the research activities of the scientific community that is spearheading war against cancer.

• Motivate and orienting life sciences and medical students towards Cancer Research.

• Actively pursuing collaborations with the institutes and organizations with activities in synergy with BICH&RI’s activities.

• Bringing awareness about cancer prevention

Values:

• The research will be carried out with Integrity, Commitment and Diligence.

• The research priorities of the institute will be governed by National priorities and Global concerns, particularly related to Cancer.

• The institute shall foster creativity to innovate.

Guiding Principles:

F.A.C.T and P.A.R

FACT: Functional, Accountable, Commitment and Trust and Transparency

PAR: Precise, Accurate and Reproducible

Research Strengths

1) DSIR recognized SIRO

2) Federal Grants:

A) Currently Funded Projects:

1) ICMR grant (3 Year grant; ~ Rs; 50,000, 00)

2) DST Young Investigator grant (3 Year grant, ~ Rs. 18,000,00).

B) Projects with grants in pipeline

1. ICMR grant (3 Year grant~ Rs. 80, 000,00).

Concept proposal approved by ICMR. Full proposal is being prepared for submission.

2. DST grant (3year grant ~ Rs. 40,000,00)

3. DBT grant (2 years-Rs. 2,00,000,00) .

Major Research Activities

Conducting Research related to;

• Gene expression (mRNA), regulators (Boundary Elements, miRNA) and polymorphisms, and gene abnormalities in relation to Cancer.

• Data which is being acquired is likely to be applied for Federal and philanthropic funds that foster collaborations between Research Institutes and Commercial Organizations.

• Investigating the anti-cancer potential of signalling molecules and commonly used dietary ingredients

• Modulating pathways to enhance presence of pro-apoptotic molecules, decrease the levels of ROS/pro-inflammatory molecules.

• Altering cell surface glycoconjugates

• Adapting Cancer Centric Genetic Tests for the benefit of the patients and to put the BIACH&RI at a different league.

• Exploring ways to introduce new ideas that will cater to the National health care initiatives.

Clinically Oriented Research:

• Cancer centric genetic tests were set up (BRCA 1, BRCA 2, CYP2D6, k-RAS, RET etc.,) for clinical setting.

• A detailed proposal for setting up comprehensive cancer genetics clinic was submitted.

• Staff members were trained for cancer centric genetic tests at ‘Advanced Centre for Treatment Research & Education in Cancer’, Navi Mumbai.

Cancer Awareness & Preventative Initiatives:

Presentations at various societies and academic institutes.

Authored a booklet titles “Plastics, Friend or Foe or Both?”

Publications in Peer Reviewed International Journals

• Sarika Daripally; Sateesh Nallapalle; Saritha Katta and Vidudala V.T.S Prasad (2015) Susceptibility to oral cancers with CD95 and CD95L promoter SNPs may vary with the site and gender. Tumor Biology DOI 10.1007/s13277-015-3516 (In Press).

• Nallapalle Sateesh, Daripally S and Prasad, V., (2014) Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently. Tumor Biol. 36(4):2709-2724. DOI: 10.1007/s13277-014-2896-7 PMID: 25472583.

• Prasad and Padma (2012), 12-Lipoxygenase heterozygosity (QQ versus QR); risk of thyroid and colorectal cancer, Familial Cancer 11, 615-621.

• Prasad et al., (2011) Association of a Functional Polymorphism (Gln261Arg) in 12-Lipoxygenase with Breast Cancer, Experimental and Therapeutic Medicine, 2, 317-323.

• Prasad and Harpreet (2011), MTHFR gene mutation (C677T) in colorectal cancer, thyroid cancer, ovarian cancer and cervical cancer. Onkologie 2011; 34: 422-426. Cited over 45 times.

Presentations & Awards

• 25 presentations were made at National and International Conferences.

Awards;

Four oral/posters were selected as the Best Presentations:

• Identification of Potential DNA Elements that may Regulate Sphingolipid Metabolizing Enzymes and Ceramide Transport Protein Using Bioinformatics Tools. *Saritha Katta, Srivani N.L.S.S, Sarika Daripally and Vidudala V.T.S Prasad, 2014, Global Cancer Conference, Hyd.

• Haplotype analysis of TP53 in oral cancer patients. Srivani et al., 2014, Global Cancer Conference, Hyd.

• Inactivating mutations of DPYD and its clinical implications. Sarika et al., 2012, Emerging Trends in Biotechnolgy, ANU, Guntur.

• Functional mutation (1522L) of CASP10 and Cancer, 2012, Vidya and Prasad Emerging Trends in Biotechnolgy, ANU, Guntur.

CLINICAL TRIALS Site Name: Basavatarakam Indo-American Cancer Hospital and Research Institute.

List of studies in 2014 and 2015

S.No

Protocol ID

National/International

(company name/ CRO)

Organ and Principal Investigator

Study status

1

BCD-022-02

International (BIOCAD)

Metastatic breast cancer

PI: Dr. Senthil J Rajappa

Ongoing

2

CRAD001Y2201(Bolero-6)

International (Novartis)

Metastatic breast cancer

PI: Dr.Senthil J Rajappa

Ongoing

3

MYL-Her3001

International (Mylan/INC Research)

Metastatic breast cancer

PI: Dr. A. Santa

Ongoing

4

RI-01-002

International (Dr.Reddy’s/Quintiles)

Diffuse large B-cell Lymphoma

PI: Dr. MVT Krishna Mohan

Ongoing

5

HCR/III/Ritux/06/2012

National (Hetero/Lambda)

Diffuse large B-cell Lymphoma

PI: Dr. MVT Krishna Mohan

Ongoing

6

2-55-52030-730/TR321

International (Ipsen Pharma/Theorem)

Carcinoid Syndrome

PI: Dr. MVT Krishna Mohan

Ongoing

7

HCR/III/BMAB/10/2013

National (Hetero/Cliantha)

Metastatic Colorectal Cancer

PI: Dr.MVT Krishna Mohan

Ongoing

8

CLDK378A2301

International (Novartis)

Non-Small Cell Lung Cancer(ALK Positive)

PI: Dr. Senthil J Rajappa

Ongoing

9

GP13-301

International(Sandoz/PPD)

Follicular Lymphoma

PI: Dr.Senthil.J.Rajappa

Ongoing

10

1200.66

International (Boehringer Ingelheim)

Non-Small Cell Lung Cancer(EGFR Mutations)

PI: Dr. Senthil J Rajappa

Ongoing

11

PKD_14_172

International (Sun Pharmaceuticals/MTR)

Metastatic breast cancer/Advanced ovarian cancer

PI: Dr. A. Santa

Ongoing

12

BM100-CC-00-I-02

National (Biocon/Clinigene)

Metastatic Colorectal Cancer(Serum Sample)

PI: Dr. Senthil J Rajappa

About to Close Out

13

GWCA0999

International (PRA Health)

Narcotic Study

PI: Dr.G.Durga Prasad

Terminated

14

MO28047

International (Roche)

Metastatic Breast Cancer

PI: Dr. Senthil J Rajappa

Close out

15

GWCA1103

International (PRA

Health )

Narcotic study

PI: Dr.G.Durga Prasad

Terminated

16

RI-02-002

National (Dr. Reddy’s/Quintiles)

Diffuse large B-cell Lymphoma (Retrospective)

PI: Dr.MVT Krishna Mohan

Close out

17

700/13

National (QPS Bio-serve)

Bio-Equivalence (Capecitabine)

PI: Dr.V.Sudhakar Kumar

Terminated

18

BCD-021-02

International (BIOCAD)

Non Squamous Non-Small Cell Lung Cancer

PI: Dr. A. Santa

Approved in Sep2013 but yet to be start

19

PT107-2009-01

International(Infinitus/Kentron) Biotech

Non-Small Cell Lung Cancer

PI: Dr.G.Durga Prasad

Ongoing